No quarterly revenue total was found in OLEMA PHARMACEUTICALS, INC.'s SEC filings.
Olema Pharmaceuticals, Inc. (OLMA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$46.1 million. As of Jun 30, 2026 it held $461.1 million in cash and investments and $660,000 in total debt.
Revenue
—
Net income
$-63.20M
-44.3% vs year-ago quarter
Operating cash flow
$-45.90M
-53.6% vs year-ago quarter
Free cash flow
$-46.12M
-53.5% vs year-ago quarter
EPS
$-0.61
-19.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
87.50M
+27.5% vs year-ago quarter
Net cash
$460.41M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OLMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1750284
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$67.2M | -$58.0M | -$50.1M | -$45.9M | -$47.9M |
| Net income | -$63.2M | -$53.1M | -$46.1M | -$42.2M | -$43.8M |
| Diluted EPS | -$0.61 | -$0.52 | -$0.50 | -$0.49 | -$0.51 |
| Operating cash flow | -$45.9M | -$46.0M | -$38.3M | -$34.5M | -$29.9M |
| Free cash flow | -$46.1M | — | — | -$34.5M | -$30.0M |
| Total assets | $486.6M | $530.6M | $533.4M | $352.5M | $382.0M |
| Total liabilities | $56.0M | $50.2M | $54.9M | $45.0M | $36.8M |
| Stockholders' equity | $430.6M | $480.5M | $478.6M | $307.5M | $345.2M |
| Cash and investments | $461.1M | $505.3M | $505.4M | $329.0M | $361.9M |
| Total debt | $660,000 | $956,000 | $1.2M | $1.5M | $1.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 15, 2026 | Oct 12, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 26, 2026 | May 26, 2026 |
All 562 Olema Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.